Virtual Library

Start Your Search

Chang-Min Choi



Author of

  • +

    P1.13 - Targeted Therapy (Not CME Accredited Session) (ID 945)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.13-32 - Comparison Between Immune-Mediated Pneumonitis and Pneumonia in Patients Treated with PD-1/PD-L1 Therapy (ID 12952)

      16:45 - 18:00  |  Author(s): Chang-Min Choi

      • Abstract
      • Slides

      Background

      Immune-mediated pneumonitis (IMP) is an uncommon but potentially fatal toxicity of anti–programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) therapy for non-small cell lung cancer. The purpose of study was to compare clinical and radiographic findings between IMP and pneumonia by pathogen.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      From 2014 to 2017, a total of 154 patients who received anti–PD-1/PD-L1 therapy were identified. Among these, IRP developed in 9 (5.8%) and pneumonia in 30 (19.5%), which were confirmed through multidisciplinary approach. CT findings (reticulation, consolidation, ground glass opacity [GGO], interlobular septal thickening, micro- [<10mm] and macro-nodules [≥10mm], bronchial wall thickening, bronchiectasis, pleural effusion, and lesion distribution/bilaterality) and clinical features (symptom, smoking history, cancer staging, laboratory findings, underlying disease, prior radiotherapy history) were compared between IRP and pneumonia. Grade and outcome of IRP were also investigated.

      4c3880bb027f159e801041b1021e88e8 Result

      In chest CT, diffuse reticulation (44.4% vs.0%, P=0.02), patchy/diffuse GGO (100% vs. 50%, P=0.01), and interlobular septal thickening (66.7% vs. 10%, P=0.002) were significantly more frequent in IRP than in pneumonia, whereas macronodule (0 vs. 36.7%, P=0.033) was significantly more common in pneumonia than IRP. IRP significantly showed peripheral location (77.8% vs. 16.7%, P=0.001) and bilateral distribution (44.4% vs. 3.3%, P=0.007). However, there were no significant differences in clinical findings between IRP and pneumonia. Among the IRP patients, 66.7% (6 of 9) of cases were grade 3, and 66.7% improved with drug holding/steroid therapy. The median onset duration of IRP from the first prescription was 126 days (range, 40-669), the median time for improvement was 43 days (range, 21-45), and the median time to death due to IRP was 18 days (range, 11-55).

      8eea62084ca7e541d918e823422bd82e Conclusion

      Several CT findings including diffuse reticulation, patchy/diffuse GGO, and interlobular septal thickening with bilateral and peripheral distribution were more frequent in IRP than pneumonia by pathogen. Clinical findings were overlapped.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.